BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cremonini F, Talley NJ. Irritable Bowel Syndrome: Epidemiology, Natural History, Health Care Seeking and Emerging Risk Factors. Gastroenterology Clinics of North America 2005;34:189-204. [DOI: 10.1016/j.gtc.2005.02.008] [Cited by in Crossref: 137] [Cited by in F6Publishing: 117] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Shankar V, Reo NV, Paliy O. Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome. Microbiome. 2015;3:73. [PMID: 26653757 DOI: 10.1186/s40168-015-0139-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
2 Tjong Y, Ip S, Lao L, Fong HH, Sung JJ, Berman B, Che C. Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome. J Ethnopharmacol. 2011;135:754-761. [PMID: 21511022 DOI: 10.1016/j.jep.2011.04.007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
3 Fan YF, Liu H, Wu YM, Wei MX. Association between interleukin-10 gene polymorphisms and susceptibility to irritable bowel syndrome: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2012; 20(26): 2519-2524 [DOI: 10.11569/wcjd.v20.i26.2519] [Reference Citation Analysis]
4 Kolida S, Saulnier D, Gibson G. Gastrointestinal Microflora: Probiotics. Advances in Applied Microbiology Volume 59. Elsevier; 2006. pp. 187-219. [DOI: 10.1016/s0065-2164(06)59007-0] [Cited by in Crossref: 22] [Article Influence: 1.4] [Reference Citation Analysis]
5 Kua CH, Ng ST, Lhode R, Kowalski S, Gwee KA. Irritable bowel syndrome and other gastrointestinal disorders: evaluating self-medication in an Asian community setting. Int J Clin Pharm 2012;34:561-8. [PMID: 22552577 DOI: 10.1007/s11096-012-9644-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
6 Kjellström L, Molinder H, Agréus L, Nyhlin H, Talley NJ, Andreasson A. A randomly selected population sample undergoing colonoscopy: prevalence of the irritable bowel syndrome and the impact of selection factors. Eur J Gastroenterol Hepatol. 2014;26:268-275. [PMID: 24384686 DOI: 10.1097/MEG.0000000000000024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
7 Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc. 2009;109:1204-1214. [PMID: 19559137 DOI: 10.1016/j.jada.2009.04.012] [Cited by in Crossref: 122] [Cited by in F6Publishing: 96] [Article Influence: 9.4] [Reference Citation Analysis]
8 Shi J, Tong Y, Shen JG, Li HX. Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: A systematic review. World J Gastroenterol 2008; 14(3): 454-462 [PMID: 18200670 DOI: 10.3748/wjg.14.454] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
9 Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11:497-505. [PMID: 24751910 DOI: 10.1038/nrgastro.2014.40] [Cited by in Crossref: 183] [Cited by in F6Publishing: 169] [Article Influence: 22.9] [Reference Citation Analysis]
10 Pimentel M, Riddle MS. Prevention of Traveler's Diarrhea: A Call to Reconvene. Clinical Infectious Diseases 2008;46:151-2. [DOI: 10.1086/524090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
11 Saito YA, Almazar AE, Tilkes KE, Choung RS, Van Norstrand MD, Schleck CD, Zinsmeister AR, Talley NJ. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019;49:389-97. [PMID: 30663077 DOI: 10.1111/apt.15077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
12 Weichselbaum E. Probiotics and health: a review of the evidence. Nutrition Bulletin 2009;34:340-73. [DOI: 10.1111/j.1467-3010.2009.01782.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
13 Arasteh P, Maharlouei N, Eghbali SS, Amini M, Lankarani KB, Malekzadeh R. A Comprehensive Look at Irritable Bowel Syndrome and its Associated Factors Considering the Rome IV Criteria: A Penalized Smoothly Clipped Absolute Deviation Regression Approach in the Pars Cohort Study. Middle East J Dig Dis 2018;10:149-59. [PMID: 30186578 DOI: 10.15171/mejdd.2018.104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Edogawa S, Peters SA, Jenkins GD, Gurunathan SV, Sundt WJ, Johnson S, Lennon RJ, Dyer RB, Camilleri M, Kashyap PC, Farrugia G, Chen J, Singh RJ, Grover M. Sex differences in NSAID-induced perturbation of human intestinal barrier function and microbiota. FASEB J 2018;:fj201800560R. [PMID: 29897814 DOI: 10.1096/fj.201800560R] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
15 Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs. 2006;66:1073-1088. [PMID: 16789793 DOI: 10.2165/00003495-200666080-00004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
16 Tack J, Schumacher K, Tonini G, Scartoni S, Capriati A, Maggi CA. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut 2017;66:1403-13. [DOI: 10.1136/gutjnl-2015-310683] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
17 Saad R, Chey WD. Tegaserod in the treatment of irritable bowel syndrome with constipation. Womens Health (Lond) 2006;2:29-42. [PMID: 19803924 DOI: 10.2217/17455057.2.1.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Dorn SD, Palsson OS, Woldeghebriel M, Fowler B, McCoy R, Weinberger M, Drossman DA. Development and pilot testing of an integrated, web-based self-management program for irritable bowel syndrome (IBS). Neurogastroenterol Motil 2015;27:128-34. [PMID: 25482042 DOI: 10.1111/nmo.12487] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
19 Lee JY, Cevallos SA, Byndloss MX, Tiffany CR, Olsan EE, Butler BP, Young BM, Rogers AWL, Nguyen H, Kim K, Choi SW, Bae E, Lee JH, Min UG, Lee DC, Bäumler AJ. High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease. Cell Host Microbe 2020;28:273-284.e6. [PMID: 32668218 DOI: 10.1016/j.chom.2020.06.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
20 Sherwin LB. Layperson's knowledge and perceptions of irritable bowel syndrome as potential barriers to care. J Adv Nurs 2018;74:1199-207. [PMID: 29319900 DOI: 10.1111/jan.13521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Xue XC, Qi XX, Wan XY. Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome. Medicine (Baltimore) 2017;96:e9235. [PMID: 29390477 DOI: 10.1097/MD.0000000000009235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Jones MP, Chey WD, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley NJ. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther 2014;39:426-37. [DOI: 10.1111/apt.12608] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
23 Dorn SD. Systematic review: self-management support interventions for irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32:513-521. [PMID: 20497137 DOI: 10.1111/j.1365-2036.2010.04374.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
24 Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil. 2008;20 Suppl 1:121-129. [PMID: 18402649 DOI: 10.1111/j.1365-2982.2008.01097.x] [Cited by in Crossref: 173] [Cited by in F6Publishing: 158] [Article Influence: 12.4] [Reference Citation Analysis]
25 De Schepper HU, De Man JG, Moreels TG, Pelckmans PA, De Winter BY. Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease - clinical relevance and pathophysiological mechanisms. Aliment Pharmacol Ther. 2008;27:621-637. [PMID: 18221407 DOI: 10.1111/j.1365-2036.2008.03624.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
26 Sahoo S, Padhy SK. Cross-cultural and psychological issues in irritable bowel syndrome. J Gastroenterol Hepatol 2017;32:1679-85. [PMID: 28244198 DOI: 10.1111/jgh.13773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Walsh K, Mcwilliams SR, Maher MM, Quigley EM. The spectrum of functional gastrointestinal disorders in a tertiary referral clinic in Ireland. Ir J Med Sci 2012;181:81-6. [DOI: 10.1007/s11845-011-0756-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
28 Maconi G, Bolzoni E, Giussani A, Friedman AB, Duca P. Accuracy and cost of diagnostic strategies for patients with suspected Crohn's disease. J Crohns Colitis. 2014;8:1684-1692. [PMID: 25179579 DOI: 10.1016/j.crohns.2014.08.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
29 Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol. 2011;46:663-672. [PMID: 21443416 DOI: 10.3109/00365521.2011.565066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
30 López-Colombo A, Morgan D, Bravo-González D, Montiel-Jarquín A, Méndez-Martínez S, Schmulson M. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. Gastroenterol Res Pract 2012;2012:606174. [PMID: 22474443 DOI: 10.1155/2012/606174] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
31 Herrick LM, Spalding WM, Saito YA, Moriarty J, Schleck C. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. J Med Econ 2017;20:273-9. [PMID: 27783533 DOI: 10.1080/13696998.2016.1253584] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
32 Pauls RN, Max JB. Symptoms and dietary practices of irritable bowel syndrome patients compared to controls: results of a USA national survey. Minerva Gastroenterol Dietol 2019;65. [DOI: 10.23736/s1121-421x.18.02518-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
33 Stacher G. Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome? Expert Rev Gastroenterol Hepatol 2007;1:15-27. [PMID: 19072430 DOI: 10.1586/17474124.1.1.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin North Am. 2010;24:961-975, ix. [PMID: 20937460 DOI: 10.1016/j.idc.2010.07.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
35 Vicario M, Alonso C, Guilarte M, Serra J, Martínez C, González-Castro AM, Lobo B, Antolín M, Andreu AL, García-Arumí E, Casellas M, Saperas E, Malagelada JR, Azpiroz F, Santos J. Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction. Psychoneuroendocrinology 2012;37:65-77. [PMID: 21641728 DOI: 10.1016/j.psyneuen.2011.05.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
36 Shafiei Z, Esfandiari F, Sarkari B, Rezaei Z, Fatahi MR, Hosseini Asl SMK. Parasitic infections in irritable bowel syndrome patients: evidence to propose a possible link, based on a case-control study in the south of Iran. BMC Res Notes 2020;13:264. [PMID: 32487206 DOI: 10.1186/s13104-020-05118-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Bharucha AE, Seide BM, Zinsmeister AR, Melton LJ 3rd. Insights into normal and disordered bowel habits from bowel diaries. Am J Gastroenterol 2008;103:692-8. [PMID: 18021288 DOI: 10.1111/j.1572-0241.2007.01631.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
38 Camilleri M, Tack JF. Current medical treatments of dyspepsia and irritable bowel syndrome. Gastroenterol Clin North Am. 2010;39:481-493. [PMID: 20951913 DOI: 10.1016/j.gtc.2010.08.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
39 Alonso C, Santos J. Editorial: A Closer Look at Mucosal Inflammation in Irritable Bowel Syndrome: Sex- and Gender-Related Disparities—Quantity, Quality, or Both? Am J Gastroenterol 2009;104:401-3. [DOI: 10.1038/ajg.2008.105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
40 Ishihara S, Aziz M, Oshima N, Mishima Y, Imaoka H, Moriyama I, Kinoshita Y. Irritable bowel syndrome and inflammatory bowel disease: infectious gastroenteritis-related disorders? Clin J Gastroenterol. 2009;2:9-16. [PMID: 26191801 DOI: 10.1007/s12328-008-0051-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
41 Darbaky Y, Evrard B, Patrier S, Falenta J, Garcin S, Tridon A, Dapoigny M, Silberberg C, Nivoliez A, Diop L. Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. J Appl Microbiol 2017;122:188-200. [PMID: 27718511 DOI: 10.1111/jam.13320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
42 Annaházi A, Ferrier L, Bézirard V, Lévêque M, Eutamène H, Ait-Belgnaoui A, Coëffier M, Ducrotté P, Róka R, Inczefi O, Gecse K, Rosztóczy A, Molnár T, Ringel-Kulka T, Ringel Y, Piche T, Theodorou V, Wittmann T, Bueno L. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol 2013;108:1322-31. [PMID: 23711626 DOI: 10.1038/ajg.2013.152] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
43 Sperber AD, Dekel R. Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes. J Neurogastroenterol Motil. 2010;16:113-119. [PMID: 20535341 DOI: 10.5056/jnm.2010.16.2.113] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
44 Cooper M, O'connor‐semmes R, Reedy BA, Hacquoil K, Gorycki P, Pannullo K, Verticelli A, Shakib S. First‐in‐Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. Clinical Pharmacology in Drug Development 2019;8:234-45. [DOI: 10.1002/cpdd.600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Linedale EC, Andrews JM. Diagnosis and management of irritable bowel syndrome: a guide for the generalist. Med J Aust. 2017;207:309-315. [PMID: 28954618 DOI: 10.5694/mja17.00457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
46 Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18:349-358. [PMID: 19243285 DOI: 10.1517/13543780902780175] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 4.7] [Reference Citation Analysis]
47 Parekh PJ, Balart LA, Johnson DA. The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. Clin Transl Gastroenterol 2015;6:e91. [PMID: 26087059 DOI: 10.1038/ctg.2015.16] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 17.0] [Reference Citation Analysis]
48 Jin Y, Lin Y, Lin L, Zheng C. IL-17/IFN-γ interactions regulate intestinal inflammation in TNBS-induced acute colitis. J Interferon Cytokine Res. 2012;32:548-556. [PMID: 23030668 DOI: 10.1089/jir.2012.0030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
49 McFarland LV. State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J Gastroenterol 2008; 14(17): 2625-2629 [PMID: 18461647 DOI: 10.3748/wjg.14.2625] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
50 Hammerle CW, Crowe SE. When to reconsider the diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am 2011;40:291-307, vii. [PMID: 21601781 DOI: 10.1016/j.gtc.2011.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Khayyatzadeh SS, Esmaillzadeh A, Saneei P, Keshteli AH, Adibi P. Dietary patterns and prevalence of irritable bowel syndrome in Iranian adults. Neurogastroenterol Motil. 2016;28:1921-1933. [PMID: 27324285 DOI: 10.1111/nmo.12895] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
52 Cañón M, Ruiz AJ, Rondón M, Alvarado J. Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian University: an electronic survey. Ann Gastroenterol 2017;30:67-75. [PMID: 28042240 DOI: 10.20524/aog.2016.0093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
53 Sikander A, Rana SV, Sinha SK, Prasad KK, Arora SK, Sharma SK, Singh K. Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population. J Clin Gastroenterol. 2009;43:957-961. [PMID: 19687750 DOI: 10.1097/mcg.0b013e3181b37e8c] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
54 Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med. 2007;69:89-98. [PMID: 17244851 DOI: 10.1097/psy.0b013e31802e2f24] [Cited by in Crossref: 143] [Cited by in F6Publishing: 63] [Article Influence: 9.5] [Reference Citation Analysis]
55 Kubo M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Tominaga K, Arakawa T. Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults. Neurogastroenterol Motil. 2011;23:249-254. [PMID: 21122032 DOI: 10.1111/j.1365-2982.2010.01640.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
56 Bundeff AW, Woodis CB. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother. 2014;48:777-784. [PMID: 24651166 DOI: 10.1177/1060028014528151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
57 Howell SC, Quine S, Talley NJ. Low social class is linked to upper gastrointestinal symptoms in an Australian sample of urban adults. Scand J Gastroenterol. 2006;41:657-666. [PMID: 16716963 DOI: 10.1080/00365520500442567] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
58 Lee V, Guthrie E, Robinson A, Kennedy A, Tomenson B, Rogers A, Thompson D. Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation. J Psychosom Res 2008;64:129-38. [PMID: 18222126 DOI: 10.1016/j.jpsychores.2007.09.004] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
59 O’malley D, Quigley EM, Dinan TG, Cryan JF. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain, Behavior, and Immunity 2011;25:1333-41. [DOI: 10.1016/j.bbi.2011.04.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
60 Ozol D, Uz E, Bozalan R, Türkay C, Yildirim Z. Relationship between asthma and irritable bowel syndrome: role of food allergy. J Asthma. 2006;43:773-775. [PMID: 17169830 DOI: 10.1080/02770900601031789] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
61 Roohafza H, Bidaki EZ, Hasanzadeh-Keshteli A, Daghaghzade H, Afshar H, Adibi P. Anxiety, depression and distress among irritable bowel syndrome and their subtypes: An epidemiological population based study. Adv Biomed Res 2016;5:183. [PMID: 28028523 DOI: 10.4103/2277-9175.190938] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
62 Yamada E, Tsunoda S, Abe T, Uchida E, Teraoka H, Watanabe S, Kawana I, Tagri M, Hosaka N, Nagai K, Nishino H, Nakajima A. Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multicenter study in Japan. J Gastroenterol 2017;52:301-7. [PMID: 27129979 DOI: 10.1007/s00535-016-1215-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Dorn SD, Farley JF, Hansen RA, Shah ND, Sandler RS. Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions. Gastroenterology 2009;137:518-24, 524.e1-2. [PMID: 19445943 DOI: 10.1053/j.gastro.2009.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
64 Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. [PMID: 24523597 DOI: 10.2147/clep.s40245] [Cited by in Crossref: 101] [Cited by in F6Publishing: 242] [Article Influence: 12.6] [Reference Citation Analysis]
65 Fernández C, Amigo I. Efficacy of training in stress and contingency management in cases of irritable bowel syndrome. Stress and Health 2006;22:285-95. [DOI: 10.1002/smi.1106] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
66 Ding Y, Lu B, Chen D, Meng L, Shen Y, Chen S. Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome. Proteomics 2010;10:2620-30. [PMID: 20461717 DOI: 10.1002/pmic.200900572] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
67 Preechavuthinant S, Willis W, Coustasse A. Trends and effects of pharmaceutical DTCA. IJPHM 2018;12:61-70. [DOI: 10.1108/ijphm-04-2017-0019] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
68 He WR, Zhang FC, Liang LX. Mixed 5-HT3 antagonists/5-HT4 agonists for irritable bowel syndrome: a systematic review. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3277-3283 [DOI: 10.11569/wcjd.v19.i31.3277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Kaji M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, Watanabe K, Watanabe T, Tominaga K, Arakawa T. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life: Overlap of FGIDs and HR-QOL. Journal of Gastroenterology and Hepatology 2010;25:1151-6. [DOI: 10.1111/j.1440-1746.2010.06249.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 119] [Article Influence: 11.6] [Reference Citation Analysis]
70 Lei WY, Chang CY, Wu JH, Lin FH, Hsu Chen C, Chang CF, Lin YR, Wu HP. An Initial Attack of Urinary Stone Disease Is Associated with an Increased Risk of Developing New-Onset Irritable Bowel Syndrome: Nationwide Population-Based Study. PLoS One 2016;11:e0157701. [PMID: 27337114 DOI: 10.1371/journal.pone.0157701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Maconi G, Magro F. Comparing techniques to achieve high accuracy and low cost: how should we first diagnose Crohn's disease? Journal of Comparative Effectiveness Research 2015;4:75-8. [DOI: 10.2217/cer.15.2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
72 Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: Is there hope? World J Gastroenterol 2011; 17(38): 4251-4257 [PMID: 22090780 DOI: 10.3748/wjg.v17.i38.4251] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
73 Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis. 2009;41:854-862. [PMID: 19665953 DOI: 10.1016/j.dld.2009.07.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
74 Pensabene L, Sestito S, Nicoletti A, Graziano F, Strisciuglio P, Concolino D. Gastrointestinal Symptoms of Patients with Fabry Disease. Gastroenterol Res Pract 2016;2016:9712831. [PMID: 26880903 DOI: 10.1155/2016/9712831] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
75 Rutter CL, Rutter DR. Longitudinal Analysis of the Illness Representation Model in Patients with Irritable Bowel Syndrome (IBS). J Health Psychol 2007;12:141-8. [DOI: 10.1177/1359105307071748] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
76 Bourgault P, Devroede G, St-cyr-tribbl D, Marchand S, Barcellos de Souza J. Help-−seeking process in women with irritable bowel syndrome. Part 2: discussion. Gastrointestinal Nursing 2009;6:28-32. [DOI: 10.12968/gasn.2009.6.10.37852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
77 Smith JL, Bayles D. Postinfectious irritable bowel syndrome: a long-term consequence of bacterial gastroenteritis. J Food Prot 2007;70:1762-9. [PMID: 17685356 DOI: 10.4315/0362-028x-70.7.1762] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
78 Knight JR, Locke GR 3rd, Zinsmeister AR, Schleck CD, Talley NJ. Family history of mental illness or alcohol abuse and the irritable bowel syndrome. J Psychosom Res 2015;78:237-41. [PMID: 25582802 DOI: 10.1016/j.jpsychores.2014.11.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
79 Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS-specific models of care? Therap Adv Gastroenterol 2017;10:727-36. [PMID: 28932273 DOI: 10.1177/1756283X17718677] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
80 Bouchoucha M, Fysekidis M, Devroede G, Raynaud J-, Bejou B, Benamouzig R. Abdominal pain localization is associated with non-diarrheic Rome III functional gastrointestinal disorders. Neurogastroenterol Motil 2013;25:686-e511. [DOI: 10.1111/nmo.12149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
81 Corsetti M, Whorwell P. Novel pharmacological therapies for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2016;10:807-15. [PMID: 26907518 DOI: 10.1586/17474124.2016.1158099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
82 Weichselbaum E. Does bread cause bloating?: Does bread cause bloating. Nutrition Bulletin 2012;37:30-6. [DOI: 10.1111/j.1467-3010.2011.01943.x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
83 Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis. 2006;43:898-901. [PMID: 16941373 DOI: 10.1086/507540] [Cited by in Crossref: 88] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
84 Prusator DK, Greenwood-Van Meerveld B. Sex-related differences in pain behaviors following three early life stress paradigms. Biol Sex Differ 2016;7:29. [PMID: 27293543 DOI: 10.1186/s13293-016-0082-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
85 Ng KS, Nassar N, Hamd K, Nagarajah A, Gladman MA. Prevalence of functional bowel disorders and faecal incontinence: an Australian primary care survey. Colorectal Dis. 2015;17:150-159. [PMID: 25359460 DOI: 10.1111/codi.12808] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
86 Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, Tayebi A, Hashemi H, Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res. 2014;3:140. [PMID: 25161987 DOI: 10.4103/2277-9175.135157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
87 Jafari P, Asadollahi Z, Moini M, Seyed Mirzaie M. Health Related Quality of Life in Iranian Patients With Irritable Bowel Syndrome: Reliability and Validity of the Persian Version of the IBS-QOL. Iran Red Crescent Med J 2013;15:723-8. [PMID: 24578842 DOI: 10.5812/ircmj.4605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
88 Martens U, Enck P, Zieseniss E. Probiotic treatment of irritable bowel syndrome in children. Ger Med Sci. 2010;8:Doc07. [PMID: 20234804 DOI: 10.3205/000096] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
89 Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, Delvaux M, Drossman DA, Foxx-Orenstein AE, Guarner F. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on Irritable Bowel Syndrome. J Clin Gastroenterol. 2012;46:356-366. [PMID: 22499071 DOI: 10.1097/mcg.0b013e318247157c] [Cited by in Crossref: 95] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
90 Chen YL, Huang XQ, Xu SJ, Liao JB, Wang RJ, Lu XF, Xie YL, Zhou FS, Su ZR, Lai XP. Relieving visceral hyperalgesia effect of Kangtai capsule and its potential mechanisms via modulating the 5-HT and NO level in vivo. Phytomedicine. 2013;20:249-257. [PMID: 23141427 DOI: 10.1016/j.phymed.2012.09.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
91 Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin Ther. 2010;32:1221-1233. [PMID: 20678672 DOI: 10.1016/j.clinthera.2010.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
92 Maruca A, Lupia A, Rocca R, Keszthelyi D, Corsetti M, Alcaro S. In Silico Food-Drug Interaction: A Case Study of Eluxadoline and Fatty Meal. Int J Mol Sci 2020;21:E9127. [PMID: 33266221 DOI: 10.3390/ijms21239127] [Reference Citation Analysis]
93 Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008;53:108-15. [PMID: 17503182 DOI: 10.1007/s10620-007-9830-4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
94 Mudipalli RS, Remes-Troche JM, Andersen L, Rao SS. Functional chest pain: esophageal or overlapping functional disorder. J Clin Gastroenterol 2007;41:264-9. [PMID: 17426464 DOI: 10.1097/01.mcg.0000225521.36160.1b] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
95 Sadeghian M, Sadeghi O, Hassanzadeh Keshteli A, Daghaghzadeh H, Esmaillzadeh A, Adibi P. Physical activity in relation to irritable bowel syndrome among Iranian adults. PLoS One 2018;13:e0205806. [PMID: 30335859 DOI: 10.1371/journal.pone.0205806] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
96 Sun S, Liu W, Li Y. CADM1 enhances intestinal barrier function in a rat model of mild inflammatory bowel disease by inhibiting the STAT3 signaling pathway. J Bioenerg Biomembr 2020;52:343-54. [PMID: 32929607 DOI: 10.1007/s10863-020-09850-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Schwille-Kiuntke J, Rüdlin SL, Junne F, Enck P, Brenk-Franz K, Zipfel S, Rieger MA. Illness perception and health care use in individuals with irritable bowel syndrome: results from an online survey. BMC Fam Pract 2021;22:154. [PMID: 34275465 DOI: 10.1186/s12875-021-01499-5] [Reference Citation Analysis]
98 Basu PP, Shah NJ, Krishnaswamy N, Pacana T. Prevalence of restless legs syndrome in patients with irritable bowel syndrome. World J Gastroenterol 2011; 17(39): 4404-4407 [PMID: 22110266 DOI: 10.3748/wjg.v17.i39.4404] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
99 Ballou SK, Keefer L. Multicultural considerations in the diagnosis and management of irritable bowel syndrome: a selective summary. Eur J Gastroenterol Hepatol. 2013;25:1127-1133. [PMID: 23778308 DOI: 10.1097/meg.0b013e3283632bf2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
100 Cremonini F, Camilleri M, Zinsmeister AR, Herrick LM, Beebe T, Talley NJ. Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population. Neurogastroenterol Motil. 2009;21:128-135. [PMID: 18823289 DOI: 10.1111/j.1365-2982.2008.01181.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
101 Cremonini F, Camilleri M, Zinsmeister AR, Herrick LM, Beebe T, Talley NJ. Sleep disturbances are linked to both upper and lower gastrointestinal symptoms in the general population. Neurogastroenterol Motil. 2009;21:128-135. [PMID: 18823289 DOI: 10.1111/j.1365-2982.2008.0181.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Heitkemper MM. Asking the why questions: a career in science. Kaohsiung J Med Sci 2010;26:S22-7. [PMID: 20538243 DOI: 10.1016/S1607-551X(10)70054-1] [Reference Citation Analysis]
103 Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14(17): 2639-2649 [PMID: 18461649 DOI: 10.3748/wjg.14.2639] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
104 Areeshi MY, Haque S, Panda AK, Mandal RK. A serotonin transporter gene (SLC6A4) polymorphism is associated with reduced risk of irritable bowel syndrome in American and Asian population: a meta-analysis. PLoS One. 2013;8:e75567. [PMID: 24069428 DOI: 10.1371/journal.pone.0075567] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
105 Li ZY, Zhang N, Wen S, Zhang J, Sun XL, Fan XM, Sun YH. Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome. Clin Res Hepatol Gastroenterol. 2017; Epub ahead of print. [PMID: 28215540 DOI: 10.1016/j.clinre.2016.12.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
106 Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am. 2011;40:1-10. [PMID: 21333897 DOI: 10.1016/j.gtc.2010.12.006] [Cited by in Crossref: 102] [Cited by in F6Publishing: 92] [Article Influence: 9.3] [Reference Citation Analysis]
107 McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14(17): 2650-2661 [PMID: 18461650 DOI: 10.3748/wjg.14.2650] [Cited by in CrossRef: 209] [Cited by in F6Publishing: 163] [Article Influence: 14.9] [Reference Citation Analysis]
108 Corsetti M, Whorwell P. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline. Expert Rev Gastroenterol Hepatol 2017;11:285-92. [PMID: 28276811 DOI: 10.1080/17474124.2017.1298442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
109 Bourgault P, Devroede G, St−cyr−tribble D, Marchand S, Barcellos de Souza J. Help−seeking process in women with irritable bowel syndrome. Part 1: study results. Gastrointestinal Nursing 2008;6:24-31. [DOI: 10.12968/gasn.2008.6.9.31775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
110 Kohen R, Jarrett ME, Cain KC, Jun SE, Navaja GP, Symonds S, Heitkemper MM. The serotonin transporter polymorphism rs25531 is associated with irritable bowel syndrome. Dig Dis Sci. 2009;54:2663-2670. [PMID: 19125330 DOI: 10.1007/s10620-008-0666-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
111 Zhou Q, Fillingim RB, Riley JL 3rd, Verne GN. Ischemic hypersensitivity in irritable bowel syndrome patients. Pain Med 2010;11:1619-27. [PMID: 21029350 DOI: 10.1111/j.1526-4637.2010.00954.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
112 Malaguarnera G, Leggio F, Vacante M, Motta M, Giordano M, Bondi A, Basile F, Mastrojeni S, Mistretta A, Malaguarnera M. Probiotics in the gastrointestinal diseases of the elderly. J Nutr Health Aging. 2012;16:402-410. [PMID: 22499466 DOI: 10.1007/s12603-011-0357-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
113 Li Y, Nie Y, Xie J, Tang W, Liang P, Sha W, Yang H, Zhou Y. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci. 2007;52:2942-2949. [PMID: 17394071 DOI: 10.1007/s10620-006-9679-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 4.2] [Reference Citation Analysis]
114 Liu ZQ, Wei MX. Inhibitory effects of Radix Saposhnikoviae on murine colonic smooth muscle strips in vitro and its mechanism. Shijie Huaren Xiaohua Zazhi 2008; 16(26): 2946-2951 [DOI: 10.11569/wcjd.v16.i26.2946] [Reference Citation Analysis]
115 Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010;10:23. [PMID: 20175924 DOI: 10.1186/1471-230x-10-23] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
116 Fabian E, Schiller D, Toplak H, Brunner-Krainz M, Fazekas F, Schoefl R, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 153: A 55-year-old woman with atypical multiple sclerosis and irritable bowel syndrome. Wien Klin Wochenschr 2018;130:151-60. [PMID: 29164318 DOI: 10.1007/s00508-017-1291-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
117 Prusator DK, Greenwood-van Meerveld B. Sex differences in stress-induced visceral hypersensitivity following early life adversity: a two hit model. Neurogastroenterol Motil 2016;28:1876-89. [DOI: 10.1111/nmo.12891] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
118 Dorn SD, Morris CB, Schneck SE, Hopper TM, Hu YJ, Kelapure R, Weinland SR, Norton WF, Norton NJ, Drossman DA. Development and Validation of the Irritable Bowel Syndrome Satisfaction With Care Scale. Clinical Gastroenterology and Hepatology 2011;9:1065-1071.e2. [DOI: 10.1016/j.cgh.2011.08.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
119 Corsetti M, Van Oudenhove L, Tack J. The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil 2014;26:1669-76. [DOI: 10.1111/nmo.12475] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
120 Fields JM, Dean AJ. Systemic causes of abdominal pain. Emerg Med Clin North Am 2011;29:195-210, vii. [PMID: 21515176 DOI: 10.1016/j.emc.2011.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
121 Rhodes DY, Wallace M. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep. 2006;8:327-332. [PMID: 16836945 DOI: 10.1007/s11894-006-0054-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]